medigraphic.com

2021, Number 4

<< Back Next >>

Rev Hematol Mex 2021; 22 (4)

Evans syndrome

Silva-Vera M, Jiménez-González MJ, Pacheco-Serrano OF, Palomino-Pérez MJ

Language: Spanish
References: 19
Page: 207-212
PDF size: 198.38 Kb.


ABSTRACT

Background: Evans syndrome is a rare chronic hematologic affection with a worldwide incidence of 1.8 per million population per year. It is characterized by the presence of two or more cytopenias, including autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura (ITP). Diagnosis is challenging as it is made by exclusion of other infectious, malignant or autoimmune diseases. Clinical presentation is induced directly by the anemia and thrombocytopenia.
Clinical case: A 22-year-old male patient diagnosed with thrombocytopenia, presenting with nonspecific, repetitive, and self-limited symptoms for 3 years. He presented episodes of epistaxis, gingivorrhage, headache with photosensitivity, and hemorrhoids. With associated ecchymosis and petechiae in extremities and oral mucosa, as well as splenomegaly. Laboratory results reported hemoglobin of 11.6 g/dL, platelets of 3000/ mm3 and positive direct Coombs test. The patient was ultimately diagnosed with Evans syndrome and hospitalized for plasmapheresis and steroids administration. Nowadays he is reported stable.
Conclusions: Evans syndrome may have remissions and exacerbations during the person’s lifetime, but it has a favorable prognosis with appropriate treatment and early recognition, so it must be an important differential diagnosis in patients with hemolytic anemia, positive Coombs, and autoimmune thrombocytopenia.


REFERENCES

  1. Audia S, Grienay N, Mounier M, Michel M, Bonnotte B.Evans’ syndrome: From diagnosis to treatment. J Clin Med 2020; 9: 1-2

  2. doi: 10.3390/jcm9123851.2. Jaime-Pérez JC, Guerra-Leal LN, López-Razo ON, Méndez-Ramírez N, Gómez-Almaguer D. Experience with Evanssyndrome in an academic referral center. Rev Bras HematolHemoter 2015; 37 (4): 230-235. doi: 10.1016/j.bjhh.2015.03.002.

  3. Córdova-Pluma VH, Vega-Lopez CA, Ortega-Chavarría MJ.Trombocitopenia inmunitaria primaria. Med Interna Mex2020; 36 (5): 660-669. https://doi.org /10.24245/mim.v36i5.3151

  4. De la Mora-Estrada MO, Garibaldi-Covarrubias R, GarcíaLee MT. Guía de Práctica Clínica, Diagnóstico y tratamientode la anemia hemolítica autoinmune. Cenetec México:Secretaría de Salud 2010.

  5. Angelopoulos A, Kirkilesis G, Kakavia K, Papanikolaou P.Diagnosis of Evans syndrome. Pan Afr Med J 2021; 38 (314):1-4. doi: 10.11604/pamj.2021.38.314.22410.

  6. Jaime-Pérez JC, Aguilar-Calderón PE, Salazar-Cavazos L,Gómez-Almaguer D, Evans syndrome: Clinical perspectives,biological insights and treatment modalities. J. Blood Med2018; 9: 171-184. doi: 10.2147/JBM.S176144.

  7. Michel M, Chanet V, Dechartres A, Morin AS, Piette JC, et al.The spectrum of Evans syndrome in adults: New insight intothe disease based on the analysis of 68 cases, Blood 2009;114 (15): 3167-3172. doi: 10.1182/blood-2009-04-215368.

  8. Al Hazmi A, Winters ME. Evans syndrome. CPC-EM 2019; 3(2): 137-139. doi: 10.5811/cpcem.2019.1.41028.

  9. Jäger U, Barcellini W, Broome CM, Gertz MA, Hill A, Hill QA,Jila B, Kuter DJ, Michel M, Montillo M, Röth A, ZeerlederSS, Berentsen S. Diagnosis and treatment of autoimmunehemolytic anemia in adults: Recommendations from theFirst International Consensus Meeting. Blood Rev 2020;41: 100648. doi: 10.1016/j.blre.2019.100648.

  10. Michalak SS, Olewicz-Gawlik A, Rupa-Matysek J, Wolny-Rokicka E, Nowakowska E, Gil L. Autoimmune hemolytic anemia:current knowledge and perspectives. Immun. Ageing2020; 17 (1): 1-16. doi: 10.1186/s12979-020-00208-7.

  11. Cooper N, Ghanima W. Immune thrombocytopenia. NEJM2019; 381: 945-55. DOI: 10.1056/NEJMcp1810479.

  12. Al-Samkari H, Kuter DJ. Immune thrombocytopenia inadults: Modern approaches to diagnosis and treatment.Semin Thromb Hemost 2020; 46 (3): 275-288. doi:10.1055/s-0039-1700512.

  13. Terrell DR, Neunert CE, Cooper N, Heitink-Pollé KM, Kruse C,Imbach P, Kühne T, Ghanima W. Immune thrombocytopenia(Itp): Current limitations in patient management. Medicina2020; 56 (12): 1-10. doi: 10.3390/medicina56120667.

  14. Mantadakis E, Farmaki E. Natural history, pathogenesis,and treatment of Evans syndrome in children. J PediatrHematol Oncol 2017; 39 (6): 413-419. doi: 10.1097/MPH.0000000000000897.

  15. Li M, Nguyen CB, Yeung Z, Sanchez K, Rosen D, Bushan S.Evans syndrome in a patient with COVID-19. Br J Haematol2020; 190 (2): 59-61. doi: 10.1111/bjh.16846.

  16. Norton A, Roberts I. Management of Evans syndrome. BrJ Haematol 2006; 132 (2): 125-137. doi: 10.1111/j.1365-2141.2005.05809.x.

  17. Vaughn JE, Anwer F, Deeg HJ. Treatment of refractory ITPand Evans syndrome by haematopoietic cell transplantation:Is it indicated, and for whom? Vox Sang 2016; 110 (1):5-11. doi: 10.1111/vox.12314.

  18. Beydoun BS, Persaud Y, Lafferty J, Callaghan MU, Savaşan S.Bortezomib treatment of steroid-refractory Evans syndromein children. Pediatr Blood Cancer 2020; 67 (12): 8-11.doi: 10.1002/pbc.28725.

  19. Bidika E, Fayyaz H, Salib M, Memin AN, Gowda AS, RallabhandiB, Cancarevic I. Romiplostim and eltrombopag inimmune thrombocytopenia as a second-line treatment.Cureus 2020; 3 (8): 1-10. doi: 10.7759/cureus.9920.




2020     |     www.medigraphic.com